ERCC1在胃癌中的表达及预后意义

Expression and prognostic significance of ERCC1 protein in gastric cancer

目的:探讨核苷酸切除修复交叉互补组1(ERCC1)在胃癌中的表达水平及其对于生存的预后意义。方法:对85例完全切除的I～III期胃癌患者进行临床病理回顾性分析和随访,免疫组化分析采用PV-9000二步法。结果:(1)ERCC1蛋白在不同性别(P=0.364)、年龄(P=0.296)、PS评分(P=0.279)、病理组织分化程度(P=0.229)和TNM分期(P=0.154)患者中的表达均无差异。(2)ERCC1蛋白表达阴性组中位生存期(31个月)明显高于阳性组(23个月),差异具有统计学意义(P=0.048)。(3)ERCC1蛋白表达阴性患者中化疗组中位生存期(35个月)高于未化疗组(25个月),差异具有统计学意义(P=0.044)。(4)COX多因素分析显示ERCC1蛋白表达水平(P=0.041)、TNM分期(P=0.000)为胃癌术后患者生存期的独立影响因素。结论:ERCC1蛋白可预测胃癌术后患者对铂类为主辅助化疗的敏感性;ERCC1蛋白表达水平是胃癌术后患者独立的生存预后因素。

Objective：To investigate the value of excision repair cross complementing group 1（ERCC1） protein expression for judgment of prognosis in gastric cancer.Methods：Eighty-five patients with stageⅠ-Ⅲ gastric cancer who underwent complete surgical resection were included in the study.They were retrospectively reviewed with immunohistochemical study.Result：（1） No differences of ERCC1 protein were found among patients with different genders,ages,performance statues,degrees of differentiation and pathological TNM stages（P=0.364,0.296,0.279,0.229 and 0.154）.（2）The survival curve of positive ERCC1 expression was significantly lower than that of negative expression,with median OS（overall survival） 23months and 31 months respectively（P=0.048）.（3）Among the patients with negative ERCC1 protein expression,the survival curve of the non-chemotherapy group was significantly lower than that of chemotherapy group,with median OS 25 months and 35 months respectively（P=0.044）.（4）COX multivariate regression analysis showed that the expression of ERCC1 protein（P=0.041） and pathological TNM stage（P=0.000） were independent prognostic factors of gastric cancer patients.Conclusion：ERCC1 may play an important role in predicting the sensitivity to platinum-based adjuvant chemotherapy,and it is also an independent prognostic factor of resectable gastric cancer patients.